Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3524-3527

  Von Hentig, Nils ^a   Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CYTOCHROME P450 3A; RITONAVIR; SAQUINAVIR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG FORMULATION; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE;

ADULT; AGE FACTORS; AGED; CYTOCHROME P-450 CYP3A; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PREGNANCY; PYRIDINES; RITONAVIR; SAQUINAVIR; SEX FACTORS; YOUNG ADULT;

EID: 67749143912     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00025-09     Document Type: Article

References (15)

1. Barrett, J. S., L. Labbe, and M. Pfister. 2005. Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. Clin. Pharmacokinet. 44:591-625.
2. Boffito, M., D. Back, M. Stainsby-Tron, A. Hill, G. Di Perri, G. Moyle, M. Nelson, J. Tomkins, B. Gazzard, and A. Pozniak. 2005. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br. J. Clin. Pharmacol. 59:38-42.
3. Cameron, D. W., A. J. Japour, Y. Xu, A. Hsu, J. Mellors, C. Farthing, C. Cohen, D. Poretz, M. Markowitz, S. Follansbee, J. B. Angel, D. McMahon, D. Ho, V. Devanarayan, R. Rode, M. Salgo, D. J. Kempf, R. Granneman, J. M. Leonard, and E. Sun. 1999. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13:213-224.
4. Dickinson, L., M. Boffito, D. J. Back, S. H. Khoo, A. L. Pozniak, P. Mugyenyi, C. Merry, R. S. Autar, D. M. Burger, and L. J. Aarons. 2008. Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J. Antimicrob. Chemother. 62:1344-1355.
5. Ford, J., M. Boffito, D. Maitland, A. Hill, D. Back, S. Khoo, M. Nelson, G. Moyle, B. Gazzard, and A. Pozniak. 2006. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J. Antimicrob. Chemother. 58:1009-1016.
6. Jullien, V., S. Urien, H. Chappuy, J. Dimet, E. Rey, G. Pons, S. Blanche, and J. M. Treluyer. 2005. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis. J. Clin. Pharmacol. 45:257-264.
7. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
8. Kilby, J. M., A. Hill, and N. Buss. 2002. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Med. 3:97-104.
9. Kurowski, M., S. T. Sawyer, A. Hill, and C. Moecklinghoff. 2003. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med. 4:94-100.
10. Lötsch, J., S. Harder, M. Sturmer, H. W. Doerr, G. Geisslinger, S. Staszewski, and N. von Hentig. 2007. Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 51:3264-3272.
11. Pugh, R. N., I. M. Murray-Lyon, J. L. Dawson, M. C. Pietroni, and R. Williams. 1973. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60:646-649.
12. Roche Laboratories Inc. 2002. Invirase product information. 27898310-0702. Roche Laboratories Inc., Newark, NJ.
13. Stephan, C., A. Carlebach, C. Rottmann, A. Haberl, B. Dauer, N. von Hentig, M. Kurowski, and S. Staszewski. 2007. Dose reduction effective in alleviating symptoms of saquinavir toxicity. Int. J. STD AIDS 18:81-84.
14. von Hentig, N., A. Muller, C. Rottmann, T. Wolf, T. Lutz, S. Klauke, M. Kurowski, B. Oertel, B. Dauer, S. Harder, and S. Staszewski. 2007. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob. Agents Chemother. 51:1431-1439.
15. von Hentig, N., G. Nisius, T. Lennemann, P. Khaykin, C. Stephan, E. Babacan, S. Staszewski, M. Kurowski, S. Harder, and A. Haberl. 2008. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir. Ther. 13:1039-1046.